Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  squamous cell lung cancer
Stage/Subtype:  squamous cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 28 for your search:
Start Over
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, S1400I, NCT02154490
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ABI-007-NSCL-003, NCI-2014-01528, 2014-003804-66, NCT02027428
Lung-MAP: Nivolumab with or without Ipilimumab as Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400I, NCI-2016-00050, NCT02154490, NCT02785952
A Phase I/II Trial of Stereotactic Body Radiation Therapy (SBRT)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 06-0691 / 201012832, NCI-2011-00543, 06-0691, 201012832, NCT00591838
Veliparib with or without Radiation Therapy, Carboplatin, and Paclitaxel in Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8811, NCI-2011-02592, CDR0000701003, CHNMC-PHII-111, PHII-111, S1206, NCT01386385
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC1125, NCI-2012-00518, 11-001987, NCT01737502
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NLG0401, NCI-2016-00186, 1504-1393, NCT02460367
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: PrE0504, NCI-2016-00523, CDX011-54, NCT02713828
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-121-01-02-09, NCI-2015-00560, NCT02387216
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15529, NCI-2015-02258, I4X-MC-JFCP, NCT02392507
TORC1/2 Inhibitor MLN0128 in Treating Patients with Stage IV or Recurrent Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9780, NCI-2015-00545, 15-249, 2015-00500, NCT02417701
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride in Treating Patients with Untreated Stage IV or Recurrent Squamous Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-054, NCI-2015-01430, NCT02525653
A Phase II Trial of AZD1775 plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18304, NCI-2015-01598, 15.06.0034, 18304, NCT02513563
Durvalumab in Treating Patients with Solid Tumors that Has Metastasized to the Brain
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201602169, NCI-2016-00411, NCT02669914
Atezolizumab, Nab-paclitaxel, and Carboplatin before Surgery in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AAAQ3153, NCI-2016-01097, NCT02716038
AZD8186 First Time In Patient Ascending Dose Study
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4620C00001, NCI-2013-02191, NCT01884285
Stereotactic Body Radiation Therapy and Chemotherapy in Treating Patients with Stage IIA-IIIA Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-113, NCI-2013-01323, NCT01899989
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15787, NCI-2015-01802, 2015-001473-40, I4T-MC-JVDF, KEYNOTE -098, NCT02443324
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CP-MGA271-03, NCI-2015-01495, NCT02475213
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16116, NCI-2015-02279, 2015-003013-14, I4T-MC-JVDJ, NCT02572687
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16177, NCI-2016-01192, 2015-005156-94, I3Y-MC-JPCE, KEYNOTE 287, NCT02779751
Palbociclib with Cisplatin or Carboplatin in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Winship3263-16, NCI-2016-01037, IRB00089583, NCT02897375
Start Over